Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone + chemotherapy in gastric/GEJ adenocarcinoma
NCT06841679Phase 3Recruiting
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Sep 2030
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 3 trial of utidelone in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Started Aug 2025; status: recruiting.
02
Drugs
utidelone
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06841679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841679.